Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 12:58:43 - browse：661

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Teladoc has a new CEO, but challenges remain the same

hotspot

WSS

Poor hospice wound care hurts patients and families

Medical device trials still don't enroll enough women, study finds

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

New report analyzes digital physical therapy solutions' effectiveness

Moderna says combo Covid

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

entertainment

Wikipedia

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Morphosys mixed study results for blood cancer drug

Jerome Adams on the need for new antivirals for Covid

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Moonlake's readout produced a cash windfall. Risks remain

Curing rare childhood diseases will falter unless Congress steps up

Guidelines to prevent youth baseball injuries need more muscle

'Essentially witchcraft:' A former naturopath takes on the field

United colonoscopy coverage change 'may cost lives,' doctors say

Statins may not be needed by millions of people, study suggests

hotspot

Deposition: Sackler embraced plan to conceal OxyContin’s strength

CRISPR pioneers react to Casgevy, first gene

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Weight loss drug costs may need more research, senator suggests

Study: Why relieving medical debt did not improve financial outcomes

'Essentially witchcraft:' A former naturopath takes on the field

hotspot

hotspot

Wikipedia

Wikipedia